We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-2.44%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$150M
AUM Growth
-$14.4M
Cap. Flow
-$5.61M
Cap. Flow %
-3.74%
Top 10 Hldgs %
87.14%
Holding
55
New
1
Increased
10
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
EQM
EQM Midstream Partners, LP
EQM
+$1.8M
2
KALV
KalVista Pharmaceuticals
KALV
+$485K
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$415K
4
MYGN icon
Myriad Genetics
MYGN
+$291K
5
CELG
Celgene Corp
CELG
+$188K

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$7.78M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$402K
3
VCYT icon
Veracyte
VCYT
+$399K
4
NKTR icon
Nektar Therapeutics
NKTR
+$338K
5
APLS
Apellis Pharmaceuticals
APLS
+$203K

Sector Composition

Rank Sector Weight
1 Healthcare 96.12%
2 Energy 2.68%
3 Consumer Discretionary 0.06%
4 Materials 0.04%
5 Consumer Staples 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$69.5M 46.29%
699,648
+1,981
+0.3% +$188K
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$40.6M 27.02%
218,380
– –
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$4.96M 3.3%
55,000
– –
EQM
4
DELISTED
EQM Midstream Partners, LP
EQM
$3.31M 2.21%
101,250
+51,250
+103% +$1.8M
QDEL icon
5
QuidelOrtho
QDEL
$1.19B
$3M 2%
48,844
– –
OXFD
6
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.83M 1.89%
170,303
+30,000
+21% +$415K
BMY icon
7
Bristol-Myers Squibb
BMY
$124B
$2.38M 1.59%
47,000
+3,000
+7% +$141K
VRML
8
DELISTED
Vermillion, Inc.
VRML
$1.68M 1.12%
3,221,933
+100,000
+3% +$66.2K
DOVA
9
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$1.4M 0.93%
50,000
– –
MASI
10
DELISTED
Masimo
MASI
$1.19M 0.79%
8,000
– –
BIIB icon
11
Biogen
BIIB
$30.4B
$1.16M 0.78%
5,000
– –
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$327M
$1.06M 0.71%
80,000
– –
HROW icon
13
Harrow
HROW
$1.74B
$1.01M 0.67%
180,000
– –
ARNA
14
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.01M 0.67%
22,000
– –
GTHX
15
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$911K 0.61%
40,000
– –
AMRN
16
Amarin Corp
AMRN
$292M
$894K 0.6%
2,950
– –
MYGN icon
17
Myriad Genetics
MYGN
$584M
$859K 0.57%
30,000
+10,000
+50% +$291K
DERM
18
DELISTED
Dermira, Inc.
DERM
$767K 0.51%
120,000
– –
ALBO
19
DELISTED
Albireo Pharma Inc
ALBO
$760K 0.51%
38,000
– –
XLRN
20
DELISTED
Acceleron Pharma
XLRN
$738K 0.49%
18,672
– –
CORT icon
21
Corcept Therapeutics
CORT
$9.72B
$707K 0.47%
50,000
– –
KPTI icon
22
Karyopharm Therapeutics
KPTI
$216M
$673K 0.45%
4,667
– –
ARVN icon
23
Arvinas
ARVN
$517M
$647K 0.43%
30,000
– –
WMGI
24
DELISTED
Wright Medical Group Inc
WMGI
$619K 0.41%
30,000
– –
DRNA
25
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$574K 0.38%
40,000
-5,000
-11% -$71.5K
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2019 Portfolio in Review

As of Q3 2019, Birchview Capital held 55 positions worth $150M, down 8.7% from $164M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Birchview Capital withdrew a net $5.61M in Q3 2019, closing 5 positions and reducing 3 holdings. Its most notable exit was Array Biopharma Inc, an estimated $7.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Consumer Discretionary.

Against the trend, Birchview Capital opened a new position in KalVista Pharmaceuticals worth $348K.

  • Birchview Capital's largest Q3 2019 buy was KalVista Pharmaceuticals: 30,000 shares worth $348K.
  • Birchview Capital added most to EQM Midstream Partners, LP in Q3 2019, an estimated $1.8M increase.
  • Birchview Capital's biggest Q3 2019 reduction was Veracyte, cutting an estimated $399K.
  • Birchview Capital fully exited Array Biopharma Inc in Q3 2019, selling an estimated $7.78M.
  • Birchview Capital's ten largest holdings make up 87% of its $150M portfolio in Q3 2019.
  • Birchview Capital opened 1 new position and closed 5 in Q3 2019.
  • Birchview Capital's portfolio value fell 8.7% quarter-over-quarter to $150M.

Based on Birchview Capital's 13F filing for Q3 2019, filed 12 Nov 2019.